COHANCE
Cohance Lifesciences Limited
Each stock's 10,000-path forecast, rendered as light.
Cohance Lifesciences Limited (COHANCE) Stock Analysis & Case Study
Is COHANCE a good buy? The data-driven verdict.
Cohance Lifesciences Limited (COHANCE) trades at ₹446,on the numbers it tread carefully, a Downstox Snapshot Score of 33/100.
On the numbers, Cohance Lifesciences Limited (COHANCE) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 158.0× earnings, ROE of 7.0%, a 53% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
COHANCE fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How COHANCE ranks against the 2,373 companies in our screener
- COHANCE's market cap of 17,053 Cr ranks in the 83rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- COHANCE's book value of ₹102 ranks in the 53rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- COHANCE's promoter holding of 57.5% ranks in the 47th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- COHANCE's 3-year profit (PAT) growth of -21.0% ranks in the 11th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- COHANCE's 3-year revenue growth of 19.0% ranks in the 72nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- COHANCE's debt-to-equity ratio of 0.10x is lower than 77% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is COHANCE overvalued? COHANCE P/E vs peers
COHANCE trades at 158.0× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
COHANCE share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 6.3y of COHANCE history (15%/yr drift, 43%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| COHANCE 2027 | ₹262 | ₹458 | ₹800 | +3% |
| COHANCE 2028 | ₹216 | ₹471 | ₹1,027 | +6% |
| COHANCE 2029 | ₹187 | ₹484 | ₹1,251 | +9% |
| COHANCE 2030 | ₹169 | ₹497 | ₹1,465 | +12% |
| COHANCE 2031 | ₹151 | ₹511 | ₹1,733 | +15% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability COHANCE goes up, or doubles?
The bull case for COHANCE
- Cohance Lifesciences Limited is part of the nifty200 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,251.
The bear case & risks
- COHANCE's P/E of 158.0x is lower than 7% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- COHANCE's return on equity of 7.0% ranks in the 37th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹187.
COHANCE volatility & expected range, how bumpy is the ride?
Over the last 6.3 years COHANCE compounded at 15%/year with annualized volatility of 43%. That volatility implies a 1-year 80% range of ₹262-₹800, the honest backbone behind any single price target.
COHANCE price forecast, the full 60-month probability fan
COHANCE price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds COHANCE hits common targets within the simulated horizon?
Full multi-horizon detail on the COHANCE price target & forecast page.
COHANCE Piotroski F-Score: 4/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. COHANCE scores 4/8, mixed financial health.
COHANCE MTF margin & leverage across 9 brokers
Margin Trading Facility lets you buy COHANCE with part of the capital. Lower margin % = higher leverage. Rates compared across 9 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| ZerodhaCHEAPEST | 37.12% | 2.7× |
| Groww | 37.35% | 2.7× |
| Dhan | 40.00% | 2.5× |
| Kotak Neo | 37.17% | 2.7× |
| Paytm Money | 100.00% | 1.0× |
| Pocketful | 37.79% | 2.6× |
| Anand Rathi | 100.00% | 1.0× |
| Bajaj Broking | 39.00% | 2.6× |
| Share India | 37.29% | 2.7× |
Compare every broker on the COHANCE MTF page.
About Cohance Lifesciences Limited: sector, index & market-cap context
Cohance Lifesciences Limited (COHANCE) is a small-cap NSE-listed company, and a constituent of the Nifty 500 index, with a market capitalisation of ₹17,053 Cr. See more stocks on our screener.
How the COHANCE Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Cohance Lifesciences Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
COHANCE analysis, FAQs
Is Cohance Lifesciences Limited (COHANCE) a good buy?
On the numbers, Cohance Lifesciences Limited (COHANCE) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 158.0× earnings, ROE of 7.0%, a 53% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is COHANCE overvalued or undervalued?
COHANCE trades at 158.0× earnings, expensive versus the ~22× long-run Nifty average.
What is the COHANCE share price target for 2031?
COHANCE's probability-weighted 2031 median target is ₹511, with an 80% range of ₹151-₹1,733 (10,000-path Monte-Carlo).
What is the probability COHANCE doubles in 5 years?
The modelled probability of COHANCE reaching ₹892 (2×) within 5 years is 28%.
What is the bull case for COHANCE?
Cohance Lifesciences Limited is part of the nifty200 universe with live, tracked fundamentals on Downstox.
What are the risks in COHANCE?
COHANCE's P/E of 158.0x is lower than 7% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. COHANCE's return on equity of 7.0% ranks in the 37th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.